Previous investigations identified tumor-suppressive effects caused by NHE1 down-regulation in many cancers, such as gastric cancer [10], leukemia [11] and glioma [12], suggesting that it could serve as a therapeutic target for human cancers [13]. Here, SLC9A1 is linked to cancer.